Pan cancer panels can be useful for in-vitro diagnostics (IVD) and as a clinical research solution. Clinically available targeted therapies are growing in number, and even more are currently being investigated or evaluated in clinical trials. These include drugs targeting specific mutated genes or activated pathways, and immunotherapy targeting tumour-specific neoantigens. And with that, it has become evident that comprehensive tumour profiling is warranted for clinical cohort analysis and clinical profiling. Simultaneous assessment of all major genetic biomarkers and drug targets in a single assay is the solution for the often-limited amount of DNA that is available for genetic analyses.

Where a comprehensive cancer panel’s MSI and TMB analysis can serve as a biomarker for response to immunotherapy, the pan-cancer content is aligned with key guidelines and clinical trials to assess biomarkers and drug targets important for targeted therapies.

Presently, we offer Illumina’s TrueSight Oncology Comprehensive (EU) DNA panel (Kroese et al.) – in short TSO500 DNA – as full assay or ready-to-run option. Aligned combination with RNA profiling is also a possibility. Send in your samples, isolated DNA, or prepared libraries, and we provide you with the analysed data generated using the dedicated variant calling software. For pricing and turnaround times please contact us.

Please either fill in this form or email us directly at oncology@genomescan.nl and we will get in touch with you to discuss your requirements.